NVO’s success in the past few years is underscored by its marketed semaglutide (GLP-1 agonist) medicines. Wegovy is a ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

05:57 EST Novo Nordisk ( NVO ): Cagrisema weight loss showed superiority over semaglutide Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,050 and keeps an Overweight rating on the shares. The firm ...